Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients.
D000818:Animals; D001711:Biotransformation; D001921:Brain / Q000378:metabolism; D002230:Carbidopa / Q000378:metabolism; D002396:Catechols / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000378:metabolism* / Q000627:therapeutic use; D051379:Mice; D010208:Papaverine / Q000031:analogs & derivatives*; D010300:Parkinson Disease / Q000188:drug therapy; D051381:Rats; D013765:Tetrahydropapaveroline / Q000031:analogs & derivatives* / Q000378:metabolism
D002396:Catechols; D007980:Levodopa; D013765:Tetrahydropapaveroline; D010208:Papaverine; D002230:Carbidopa